chartexchange

Roivant eyes Lisraya label expansion on Phase III uveitis win  

Clinical Trials Arena | Oct 22, 2026 6:54 AM EDT

Analysts are currently heralding the potential of Roivant's Lisraya to act as a competitor for the standard of care title in NIU.
The post Roivant eyes Lisraya label expansion on Phase III uveitis win   appeared first on Clinical Trials Arena .

Read original article